Cardinal Health to offer MicroPhage's one-day antibiotic-resistance test to NA customers
This article was originally published in Clinica
Executive Summary
Privately-held MicroPhage is to see its first product, an antibiotic susceptibility and resistance test, distributed to hospitals and healthcare centres across North America, after striking a deal with multi-billion-dollar healthcare products and services provider Cardinal Health. The latter will be the exclusive distributor of the recently FDA-cleared KeyPath MRSA/MSSA blood culture test – BT, which provides same-day results to confirm the presence of Staphylococcus aureus and identify whether the bacteria is either methicillin-resistant or –susceptible. Additionally, under the agreement, Cardinal Health will have exclusive rights to other products in Longmont, Colorado-based MicroPhage's pipeline which test blood culture specimens for S aureus. In exchange for these rights, Cardinal will invest in Cardinal for an undisclosed amount to help fund the development and commercialisation of these new products.